Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company developing novel, small molecule precision medicines for renal, cardiovascular, and metabolic diseases. They utilize their Compass platform to identify genetic variants linked to disease pathways, enabling the creation of targeted therapies. Their pipeline is led by two programs, MZE829 and MZE782, addressing significant unmet needs in kidney disease.
Buy Funded Startups lists
Funding Round: Series D
Funding Amount: $115M
Date: 03-Dec-2024
Investors: Frazier Life Sciences, Deep Track Capital, Janus Henderson Investors, Logos Capital, Third Rock Ventures, ARCH Venture Partners, Matrix Capital Management, GV, General Catalyst, Andreessen Horowitz, Foresite Capital, Woodline Partners LP, Casdin Capital, Piper Heartland Healthcare Capital, Moore Strategic Ventures
Markets: Biotechnology, Pharmaceuticals, Precision Medicine, Genetics, Therapeutics
HQ: South San Francisco, California, United States
Founded: 2017
Website: https://www.mazetx.com
LinkedIn: https://www.linkedin.com/company/mazetx/
Twitter: https://twitter.com/MazeInBiotech
Crunchbase: https://www.crunchbase.com/organization/maze-therapeutics/
Leave a Comment
Comments
No comments yet.